Literature DB >> 12154051

Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo.

Renu Wadhwa1, Lorel Colgin, Tomoko Yaguchi, Kazunari Taira, Roger R Reddel, Sunil C Kaul.   

Abstract

MKT-077, a cationic rhodacyanine dye analogue, causes selective toxicity to cancer cells. Its cellular targets elucidated thus far include oncogenic Ras, F-actin, mortalin (hmot-2)/mthsp70, and telomerase. Here we report that MKT-077 causes growth arrest of cancer cells in culture independent of their Ras, p53, or telomerase status. Telomerase activity is inhibited in vitro by MKT-077 in the telomerase assay used. However, the in vivo toxicity seen in telomerase-positive cancer cells was not accompanied by inhibition of telomerase activity or telomere shortening. Furthermore, cells with an alternative mechanism for lengthening of telomeres were also sensitive to MKT-077 and showed enhanced formation of alternative mechanism for lengthening of telomeres-associated PML bodies in their nuclei. The data suggested that inhibition of telomerase activity is unlikely to be a prime cause of MKT-077-induced toxicity in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154051

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents.

Authors:  Xiaokai Li; Sharan R Srinivasan; Jamie Connarn; Atta Ahmad; Zapporah T Young; Adam M Kabza; Erik R P Zuiderweg; Duxin Sun; Jason E Gestwicki
Journal:  ACS Med Chem Lett       Date:  2013-11-14       Impact factor: 4.345

Review 2.  Chaperone proteins and brain tumors: potential targets and possible therapeutics.

Authors:  Michael W Graner; Darell D Bigner
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

3.  Telomere maintenance in childhood primitive neuroectodermal brain tumors.

Authors:  Domenico Didiano; Tarek Shalaby; Doris Lang; Michael A Grotzer
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

4.  Identification and functional characterization of nuclear mortalin in human carcinogenesis.

Authors:  Jihoon Ryu; Zeenia Kaul; A-Rum Yoon; Ye Liu; Tomoko Yaguchi; Youjin Na; Hyo Min Ahn; Ran Gao; Il-Kyu Choi; Chae-Ok Yun; Sunil C Kaul; Renu Wadhwa
Journal:  J Biol Chem       Date:  2014-07-10       Impact factor: 5.157

Review 5.  Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70).

Authors:  Xiaokai Li; Hao Shao; Isabelle R Taylor; Jason E Gestwicki
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

6.  Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.

Authors:  Nupur Nigam; Abhinav Grover; Sukriti Goyal; Shashank P Katiyar; Priyanshu Bhargava; Pi-Chao Wang; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

7.  SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.

Authors:  Ming-Bo Huang; Jennifer Y Wu; James Lillard; Vincent C Bond
Journal:  Oncotarget       Date:  2019-09-10

8.  Mitochondria-targeting fluorescent molecules for high efficiency cancer growth inhibition and imaging.

Authors:  Hao Chen; Jing Wang; Xin Feng; Mark Zhu; Simon Hoffmann; Alex Hsu; Kun Qian; Daijuan Huang; Feng Zhao; Wei Liu; Huimao Zhang; Zhen Cheng
Journal:  Chem Sci       Date:  2019-07-08       Impact factor: 9.825

9.  Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1.

Authors:  Hazna Noor Meidinna; Seyad Shefrin; Anissa Nofita Sari; Huayue Zhang; Jaspreet Kaur Dhanjal; Sunil C Kaul; Durai Sundar; Renu Wadhwa
Journal:  Front Cell Dev Biol       Date:  2022-09-12

10.  The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast.

Authors:  Haidan Jin; Meiying Ji; Liyan Chen; Qixiang Liu; Shuanlong Che; Ming Xu; Zhenhua Lin
Journal:  J Exp Clin Cancer Res       Date:  2016-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.